Advanced Gene & Cell Technologies (AGCT) , a resident startup of the Skolkovo Foundation’s biomed cluster, has received the first tranche of investment from the RBV Capital venture fund allocated to carry out Russia’s first clinical practice...
Infectex , a resident of the Skolkovo Foundation’s biomed cluster, has completed clinical trials in Russia of its new drug for treating TB, the company announced on Friday, World Tuberculosis Day. The drug – SQ109 – has demonstrated high...